Across
- 1. the response restored by LIBTAYO
- 3. color of LIBTAYO
- 6. generates fully human therapeutic antibodies, including LIBTAYO
- 8. 360 mg infusion, every 3 weeks
- 11. first line immune response
- 12. criteria used to select patients for clinical trials
- 14. LIBTAYO______ enhances patient access to LIBTAYO
- 15. approves drug indications
- 17. immune function inhibited by LIBTAYO
- 18. number of approved FDA indications for LIBTAYO
- 19. action taken when a patient experiences a severe adverse reaction
Down
- 2. expresses programmed death receptor
- 4. tumor staging criteria
- 5. LIBTAYO biologic
- 7. objective response rate. Duration of response. Complete response rate. Safety and tolerability.
- 9. administration method of LIBTAYO
- 10. Information resource that contains efficacy, safety, and usage information for LIBTAYO
- 13. method to confirm objective response rate (ORR)
- 14. profile in which adverse reactions are reported
- 16. organization of clinical trials